GnRH agonist and Letrozole
PreclinicalSmall molecule
GnRH agonist and Letrozole is one of 70 small molecule programs targeting Adenomyosis. It is currently in Preclinical.
2
Indications
2
Total Trials
2
Active Trials
69
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
62 competitors in Endometrial Carcinoma
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Lenvima
EisaiPhase 3
Depo-Provera
Eli LillyPhase 3
Paraplatin
AAvyxa
Phase 3
Herceptin
OOrganon and Co
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Keytruda
Merck & Co.Phase 2
Megace
Bristol-Myers SquibbPhase 2
Afinitor
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GnRH agonist and Letrozole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IIndira IVF Hospital Pvt Ltd